IP Library › Granted Patent US 9,540,355
Granted Patent B2
US 9,540,355 · App. 14/761,030 · Granted Jan 10, 2017

Irciniastatin analogues

Inventors: Amos B. Smith, III (Merion, PA); Chihui An (Philadelphia, PA); Adam T. Hoye (Bala Cynwyd, PA)
Assignee: The Trustees Of The University Of Pennsylvania
C07D407/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,540,355
App. No.
14/761,030
Granted
Jan 10, 2017
Kind
B2
Abstract

The present invention is directed to irciniastatin analogs. Uses of these analogs also described.

Claims (33)

1. A compound of Formula I, or a stereoisomer thereof,

wherein

R 1 is hydrogen; and

R 2 is halogen, O—C(O)phenyl, O—C(O)C 1-6 alkyl, or C 1-6 alkyl, or wherein R 1 and R 2 together form ═CR 3 R 4 or ═NR 5 wherein R 3 and R 4 are independently hydrogen or C 1-6 alkyl, and R 5 is O—C 1-6 alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , or a stereoisomer thereof, wherein R 2 is halogen.

3. The compound of claim 2 , or a stereoisomer thereof, wherein R 2 is F.

4. The compound of claim 1 , or a stereoisomer thereof, wherein R 2 is —OC(O)phenyl.

5. The compound of claim 1 , or a stereoisomer thereof, wherein R 2 is —OC(O)C 1-6 alkyl.

6. The compound of claim 5 , or a stereoisomer thereof, wherein R 2 is

—OC(O)CH 3 .

7. The compound of claim 1 , or a stereoisomer thereof, wherein R 2 is

—C 1-6 alkyl.

8. The compound of claim 1 , or a stereoisomer thereof, wherein R 1 and R 2 together are ═CR 3 R 4 .

9. The compound of claim 8 , or a stereoisomer thereof, wherein R 3 and R 4 are each hydrogen.

10. The compound of claim 8 , or a stereoisomer thereof, wherein R 3 and R 4 are each C 1-6 alkyl.

11. The compound of claim 8 , or a stereoisomer thereof, wherein R 3 and R 4 are independently hydrogen and C 1-6 alkyl.

12. The compound claim 1 , or a stereoisomer thereof, wherein R 1 and R 2 together are ═NR 5 .

13. The compound of claim 12 , or a stereoisomer thereof, wherein R 5 is —OCH 3 .

14. The compound of claim 1 , or a stereoisomer thereof, wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1 , or a stereoisomer thereof, wherein the compound is

16. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 19, 2015
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036897/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2015
From: SMITH, AMOS B., III; AN, CHIHUI; HOYE, ADAM T.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 036092/0275 →
Continuity (2)
Provisional Application 61752508 · Jan 15, 2013
Related Publication 20150344462A1 · Dec 3, 2015